Compare AbbVie Inc (ABBV) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Nasdaq Inc — how do they compare? AbbVie Inc trades at $249.21 (market cap $441.94B), while Nasdaq Inc trades at $95.08 (market cap $53.11B). The key difference: AbbVie Inc is far larger — about 8.3× Nasdaq Inc's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | NDAQ | |
|---|---|---|
Market Cap | $441.94B | $53.11B |
Sector | Health | Financials |
52-Week High | $263.58 | $100.98 |
52-Week Low | $197.38 | $76.85 |
Enterprise Value | $506.19B | $59.57B |
Dividend Yield | 2.77% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Nasdaq (NDAQ) trades at $95.62, up 1.09% today, with strong technical momentum and consistent earnings beats. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. The company announced the acquisition of LeveL Markets, advancing its always-on markets strategy, and maintains a bullish analyst consensus.
Outlook remains positive with a consensus price target of $109.20, offering ~14% upside. Risks include market volatility sensitivity and integration challenges from acquisitions. Solid profitability and strategic growth initiatives support a favorable investment case, though macroeconomic headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
